BTIG Research assumed coverage on shares of Eidos Therapeutics (NASDAQ:EIDX) in a research note published on Wednesday morning, Benzinga reports. The brokerage issued a buy rating and a $38.00 price objective on the stock.

A number of other analysts also recently issued reports on EIDX. JPMorgan Chase & Co. downgraded Eidos Therapeutics from an overweight rating to a neutral rating and set a $29.00 price objective on the stock. in a research note on Wednesday, January 23rd. BMO Capital Markets started coverage on Eidos Therapeutics in a research report on Friday, February 22nd. They set an outperform rating and a $28.00 target price on the stock. Finally, Zacks Investment Research downgraded Eidos Therapeutics from a hold rating to a sell rating in a research report on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of Buy and an average target price of $28.57.

NASDAQ:EIDX opened at $23.58 on Wednesday. Eidos Therapeutics has a 1 year low of $8.89 and a 1 year high of $25.55. The company has a market capitalization of $868.19 million and a price-to-earnings ratio of -12.68.

Eidos Therapeutics (NASDAQ:EIDX) last released its quarterly earnings data on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.01). On average, sell-side analysts expect that Eidos Therapeutics will post -1.3 earnings per share for the current year.

In other news, insider Jonathan C. Fox sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $23.11, for a total transaction of $115,550.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Christine Siu sold 11,913 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $19.66, for a total value of $234,209.58. The disclosure for this sale can be found here.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Eidos Therapeutics by 57.9% during the 4th quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after purchasing an additional 421,666 shares during the last quarter. Aisling Capital Management LP bought a new position in Eidos Therapeutics in the 4th quarter valued at $15,461,000. Victory Capital Management Inc. bought a new position in Eidos Therapeutics in the 4th quarter valued at $2,835,000. Vanguard Group Inc grew its position in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock valued at $1,983,000 after acquiring an additional 148,673 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc. now owns 198,673 shares of the company’s stock valued at $1,983,000 after acquiring an additional 148,673 shares during the last quarter. 30.15% of the stock is currently owned by hedge funds and other institutional investors.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

See Also: Understanding Options Trading

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.